

Jianguo Wen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10405628/publications.pdf>

Version: 2024-02-01

22
papers

581
citations

567281

15
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

941
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Detection of Mycoplasma-Infected Cells by an ssDNA Aptamer Probe. ACS Sensors, 2019, 4, 2028-2038.	7.8	15
2	Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy. Small, 2019, 15, e1900903.	10.0	58
3	Improved survival in multiple myeloma, with a diminishing racial gap and a widening socioeconomic status gap over three decades. Leukemia and Lymphoma, 2018, 59, 49-58.	1.3	20
4	Cellular function reinstatement of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing. Journal of Hematology and Oncology, 2017, 10, 119.	17.0	20
5	Aptamer Internalization via Endocytosis Inducing S-Phase Arrest and Priming Mave-1 Lymphoma Cells for Cytarabine Chemotherapy. Theranostics, 2017, 7, 1204-1213.	10.0	15
6	ssDNA Aptamer Specifically Targets and Selectively Delivers Cytotoxic Drug Doxorubicin to HepG2 Cells. PLoS ONE, 2016, 11, e0147674.	2.5	11
7	Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. International Journal of Cancer, 2015, 136, 991-1002.	5.1	15
8	SDF-1 α stiffens myeloma bone marrow mesenchymal stromal cells through the activation of RhoA/RhoGAP1/ROCK1 pathway. International Journal of Cancer, 2015, 136, E219-29.	5.1	9
9	High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. British Journal of Haematology, 2014, 166, 711-719.	2.5	10
10	Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach. Bioinformatics, 2014, 30, 1899-1907.	4.1	40
11	Targeting the Biophysical Properties of the Myeloma Initiating Cell Niches: A Pharmaceutical Synergism Analysis Using Multi-Scale Agent-Based Modeling. PLoS ONE, 2014, 9, e85059.	2.5	26
12	Cancer Stem Cells: A Review of Potential Clinical Applications. Archives of Pathology and Laboratory Medicine, 2013, 137, 1111-1116.	2.5	38
13	Overexpression of Cancer Testis Antigen Genes in Multiple Myeloma Stem Cell-Like Cells. FASEB Journal, 2013, 27, 53.8.	0.5	0
14	A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes. Molecular BioSystems, 2012, 8, 1366.	2.9	19
15	Selective gene transfection of individual cells in vitro with plasmonic nanobubbles. Journal of Controlled Release, 2011, 152, 286-293.	9.9	75
16	Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth <i>in vitro</i> and <i>in vivo</i> . Molecular Cancer Therapeutics, 2011, 10, 148-158.	4.1	13
17	Drug Inhibition Profile Prediction for NF- κ B Pathway in Multiple Myeloma. PLoS ONE, 2011, 6, e14750.	2.5	28
18	Unique biomechanical interactions between myeloma cells and bone marrow stroma cells. Progress in Biophysics and Molecular Biology, 2010, 103, 148-156.	2.9	15

#	ARTICLE	IF	CITATIONS
19	Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. <i>Leukemia Research</i> , 2010, 34, 85-92.	0.8	49
20	Bone Marrow Stromal Cells From Myeloma Patients Support the Growth of Myeloma Stem Cells. <i>Stem Cells and Development</i> , 2010, 19, 1289-1296.	2.1	35
21	p38 Mitogen-Activated Protein Kinase and Hematologic Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2009, 133, 1850-1856.	2.5	27
22	P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2008, 140, 169-180.	2.5	43